REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) — Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and James Hambrick Master Clinician in Innovation.
“We are pleased to welcome Dr. Mehdi Shishehbor to our team. Dr. Shishehbor is an internationally recognized thought leader in thromboembolic diseases and brings extensive clinical and scientific expertise that will contribute to our mission to deliver pioneering products to help patients suffering from peripheral thromboembolic diseases,” commented Mojgan Saadat, President and Co-founder, Inquis Medical. “His clinical perspective will help Inquis Medical build technologies that best support the clinician, driving adoption and improved outcomes.”
In the United States, up to 900,000 individuals annually experience venous thromboembolism (VTE), with over 50% of deep vein thrombosis cases leading to pulmonary embolism.1 Current lytic-free aspiration thrombectomy procedures are limited by drawbacks that include substantial blood loss and procedural inefficiencies. Inquis Medical aims to address these limitations by developing advanced treatment options for the management of thromboembolic diseases.
“I am excited to join the Inquis Medical team. Their novel solution tackles the pain points inherent in current VTE treatment approaches and underscores the forward-thinking approach of the Inquis team,” said Dr. Shishehbor. “Inquis Medical’s thrombectomy system enhances procedural efficiency by providing operators with improved control and precision. I look forward to collaborating with this innovative team.”
The Company is also pleased to announce that Bruce Shook has joined its Board of Directors as an independent director. Most recently, he was the CEO of Intact Vascular and Vesper Medical, two peripheral vascular companies acquired by Royal Philips.
“Bruce Shook brings over three decades of experience to Inquis Medical. His stellar track record of successfully developing and commercializing new medical technologies will be invaluable to Inquis Medical, as we prepare to bring our transformative technology to the thrombectomy market,” added Vahid Saadat, CEO and Co-founder, Inquis Medical.
“I’m delighted to join the Board of Directors of Inquis Medical. The company’s unique thrombectomy technology and approach address important unmet needs in the treatment of thromboembolic disease, and I look forward to supporting the company’s continued growth,” said Bruce Shook.
About Dr. Shishehbor
Dr. Mehdi Shishehbor is currently President of the Harrington Heart and Vascular Institute, University Hospitals, Director, Interventional Cardiovascular Center, University Hospitals, Co-Director, Vascular Center, Harrington Heart and Vascular Institute, University Hospitals and Professor, CWRU School of Medicine.
He has led numerous international trials and is a National Institutes of Health scholar and winner of numerous national and international awards, including the prestigious Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award and the VIVA/LINC Young Leader’s Award in Vascular.
A widely published author and researcher, Dr. Shishehbor’s work on cardiovascular epidemiology and interventional cardiology outcomes and techniques has been published in leading medical journals including NEJM, JAMA, Circulation, JACC, Circulation Intervention, and JACC Intervention. Dr Shishehbor is the co-founder of the internationally known not-for-profit Cardiovascular Innovations (CVI) and has trained over 400 physicians on endovascular techniques. He served as the Director of Endovascular Services at Cleveland Clinic from 2009 to 2017.
About Bruce Shook
Bruce Shook is a seasoned medical technology entrepreneur with over 35 years of industry experience, including multiple early-stage ventures, focused in cardiac surgery, cardiology, neurosurgery, psychiatry, and vascular disease. In 2016, Mr. Shook formed Vesper Medical as a spinout of Intact Vascular, where he served as President and CEO. Both Intact Vascular and Vesper Medical were later acquired by Royal Philips. Mr. Shook co-founded Neuronetics [Nasdaq: STIM] and served as director, President and CEO at the company. Additionally, Mr. Shook served as co-founder, Director, President, and CEO of Neuron Therapeutics, a venture-backed company working on a drug/device product for CNS disorder treatment. He also was the President at Abiomed [NASDAQ: ABMD], where he successfully obtained PMA approval for the first, FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.
Mr. Shook has served on several corporate boards, including Devoro Medical (acquired by Boston Scientific), Surgiquest (acquired by Conmed), Respicardia (acquired by Zoll), and CoTherix (acquired by Actelion). Currently, he serves as the Board Chair for Life Sciences PA and the Penn State Research Foundation.
About Inquis Medical
Inquis Medical is a clinical stage medical device company focused on peripheral vascular innovations. The company is developing a next-generation thrombectomy technology that offers physicians improved control and precision, enhances procedural efficiency, and minimizes blood loss. Founded in 2020, Inquis Medical is led by a seasoned executive team with over three decades of combined experience in developing, launching, and supporting novel physician-tested medical devices that address unmet clinical needs and deliver lasting impact. For more information, visit www.inquismedical.com and follow us on LinkedIn.
Inquiries:
Mojgan Saadat
info@inquismedical.com
References:
1. https://www.cdc.gov/ncbddd/dvt/infographic-impact.html
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d56c49ac-5baf-4ab2-b0dd-eb6c1c035eee
https://www.globenewswire.com/NewsRoom/AttachmentNg/6a216d18-8ef8-4cef-af33-946b127c47e9
